Edition:
United States

Flex Pharma Inc (FLKS.OQ)

FLKS.OQ on NASDAQ Stock Exchange Global Market

3.54USD
3:59pm EST
Change (% chg)

$-0.18 (-4.84%)
Prev Close
$3.72
Open
$3.72
Day's High
$3.72
Day's Low
$3.54
Volume
4,115
Avg. Vol
9,510
52-wk High
$6.46
52-wk Low
$2.68

Chart for

About

Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act... (more)

Overall

Beta: --
Market Cap(Mil.): $66.86
Shares Outstanding(Mil.): 17.97
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Flex Pharma Inc - ‍Completed Enrollment In Its Phase 2 Exploratory Spasticity Study In Multiple Sclerosis With Approximately 50 Patients In Australia​

* FLEX PHARMA INC - ‍COMPLETED ENROLLMENT IN ITS PHASE 2 EXPLORATORY SPASTICITY STUDY IN MULTIPLE SCLEROSIS WITH APPROXIMATELY 50 PATIENTS IN AUSTRALIA​ Source text for Eikon: Further company coverage:

Nov 28 2017

BRIEF-Flex Pharma Q3 loss per share $0.54

* Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S

Nov 06 2017

BRIEF-Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS

* Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS

Nov 06 2017

BRIEF-Flex Pharma initiates CMT phase 2 trial with FLX-787 in US

* Flex Pharma Inc - ‍expects to report topline results from this study in middle of 2018​ Source text for Eikon: Further company coverage:

Oct 16 2017

BRIEF-Flex Pharma says on Aug 23, board unanimously voted to increase the size of co's board of directors to nine members ‍​- SEC filing

* Flex Pharma says on Aug 23, board unanimously voted to increase the size of co's board of directors to nine members ‍​- SEC filing

Aug 28 2017

BRIEF-Flex Pharma Q2 loss per share $0.51

* Q2 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S

Aug 02 2017

BRIEF-Flex Pharma initiates ALS phase 2 trial with flx-787 in U.S.

* Says expects to report topline results from this study in middle of 2018

Aug 01 2017

BRIEF-Flex Pharma names William Mcvicar president and chief executive officer

* Flex pharma names William Mcvicar president and chief executive officer

Jul 31 2017

BRIEF-FDA grants fast track designation to Flex Pharma’s FLX-787

* FDA grants fast track designation to Flex Pharma’s FLX-787 for the treatment of severe muscle cramps associated with ALS

Jul 25 2017

Earnings vs. Estimates